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Coevolution of virus and host is a process that emerges in persistent virus infections. Here we studied
the coevolutionary development of coxsackievirus B3 (CVB3) and cardiac myocytes representing the major
target cells of CVB3 in the heart in a newly established persistently CVB3-infected murine cardiac myocyte
cell line, HL-1CVB3. CVB3 persistence in HL-1CVB3 cells represented a typical carrier-state infection with
high levels (106 to 108 PFU/ml) of infectious virus produced from only a small proportion (approximately
10%) of infected cells. CVB3 persistence was characterized by the evolution of a CVB3 variant (CVB3-HL1)
that displayed strongly increased cytotoxicity in the naive HL-1 cell line and showed increased replication
rates in cultured primary cardiac myocytes of mouse, rat, and naive HL-1 cells in vitro, whereas it was
unable to establish murine cardiac infection in vivo. Resistance of HL-1CVB3 cells to CVB3-HL1 was
associated with reduction of coxsackievirus and adenovirus receptor (CAR) expression. Decreasing host
cell CAR expression was partially overcome by the CVB3-HL1 variant through CAR-independent entry
into resistant cells. Moreover, CVB3-HL1 conserved the ability to infect cells via CAR. The employment
of a soluble CAR variant resulted in the complete cure of HL-1CVB3 cells with respect to the adapted virus.
In conclusion, this is the first report of a CVB3 carrier-state infection in a cardiomyocyte cell line,
revealing natural coevolution of CAR downregulation with CAR-independent viral entry in resistant host
cells as an important mechanism of induction of CVB3 persistence.
The understanding of viral diseases has been drastically im-
proved in the last decades, and it is becoming evident that
sustained virus-host altercations can lead to the establishment
of persistent infections in humans and animals by many cyto-
lytic viruses. The mechanisms involved in the development of
virus persistence, however, are often not well understood. It
has been proposed that the in vivo innate and humoral immune
response represents the most important factor involved in the
development of virus persistence. Immunological pressure may
result in selection of attenuated or defective virus mutants that
escape immunological clearance, leading to persistent virus
infection (46). In vitro models are much simpler than in vivo
models and have therefore facilitated the study of both the
cellular and the viral components of persistent viral infections.
Certain cytolytic viruses can establish persistent infections in
vitro as well as in vivo (4, 5, 8, 28, 39). Persistent in vitro
infections can be divided into two major groups. One group
involves steady-state infections, which are characterized by vi-
rus infection of all cells. The virus, however, is unable to
accomplish the typical lytic replication cycle. The other group
includes carrier-state virus infections. These are characterized
by a cytolytic infection (yielding high progeny numbers) of a
small proportion of cells, which spares the majority of cells in
culture from cytolysis (21–24, 39, 40).
Persistent viral infection occurring in vitro seems to result
from coevolution of host cell resistance and virus virulence and
develops over a prolonged period of interaction of virus with
cell (1, 13, 24, 50, 68). For several viruses and virus families,
such as foot and mouth disease virus (62), reoviruses (1),
enteroviruses (23, 24, 28), coronaviruses (6), hepatitis C virus
(68), and autonomous parvovirus (54), coevolution of cells and
viruses following in vitro infection has been demonstrated. Mo-
lecular analysis revealed some key mechanisms, including mu-
tations of the receptor and reduction of virus receptor expres-
sion (7, 24, 50), obstacles in post receptor events during the
viral uptake process (14), and intracellular blocking of virus
replication (13), that seem to be involved in establishing car-
rier-state infections in vitro. On the other hand, development
of virus mutants that exhibit increased avidity to downregu-
lated cellular receptors (6, 7), acquisition of epitope variants
that enable alternative virus receptor usage (6), emergence of
replication-defective virus mutants (23), and generation of
small-plaque virus variants with new replication intermediates
and requirements (29) during cell virus coevolution in vitro
have also been reported.
The genus Enterovirus belongs to the family Picornaviridae,
and the species that infect humans are further divided into
human rhinoviruses A, B, and C and human enteroviruses A,
B (including type B coxsackievirus), C (including poliovirus),
and D. Enteroviruses are characterized by a single-stranded
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(positive) RNA genome packaged in a capsid containing four
capsid proteins (VP1 to VP4) (42, 47). In particular, coxsackie-
viruses of group B (CVB) (serotypes 1 to 6) have been estab-
lished as highly prevalent human pathogens and are known to
be associated with a variety of acute and chronic forms of
diseases, including myocarditis, meningitis, and pancreatitis
(31, 41, 42, 58). Cardiac infection with coxsackievirus B3
(CVB3) can result in acute myocarditis that spontaneously
resolves or chronic myocarditis with prolonged viral persis-
tence. Long-term sequelae of chronic cardiac CVB3 infection
include heart failure and development of dilated cardiomyop-
athy (DCM) with an adverse prognosis (48, 49).
The molecular mechanisms leading to induction and main-
tenance of CVB3 persistence in the human heart as well as in
experimental murine models are poorly understood. More-
over, adaptation of the immune system resulting from altera-
tions in the immunological pressure adds complexity to the in
vivo situation, making it difficult to separate immune evasion
from such alterations leading to modified replication and viral
entry.
In vitro cell systems with carrier-state virus infections have
been shown to provide a useful approach for identifying factors
regulating viral persistence (23, 51). To investigate mecha-
nisms of CVB3 persistence in cardiac cells, a CVB3 carrier-
state infection of primary human myocardial fibroblasts
(HMF) was established several years ago (27, 28). Unfortu-
nately, cardiomyocytes, not fibroblasts, represent the major
target cells of CVB3 in a healthy human heart, thus limiting the
suitability of persistently CVB3-infected HMF cells as a model
(35).
We have established a persistently CVB3-infected murine
cardiac cell line, HL-1CVB3, as a more relevant model. The
persistently infected HL-1CVB3 cell line showed a typical car-
rier-state infection, with continuous delivery of high titers of
CVB3 from a low proportion of infected cells. The expression
of the coxsackievirus and adenovirus receptor (CAR) was in-
vestigated as a key factor associated with resistance of HL-
1CVB3 cells to infection, and the entry, replication rate, and
receptor usage of the resulting CVB3-HL1 progeny virus were
examined to evaluate coevolutionary viral adaptations that
emerged during virus persistence.
MATERIALS AND METHODS
Viruses. CVB-3 (Nancy strain; VR-30) was obtained from the American Type
Culture Collection (ATCC) and propagated in HeLa cells. CVB3-HL1 is the
variant of the CVB3 Nancy strain that emerged during persistent infection in
HL-1CVB3 cells. CVB3 was collected from the supernatant of HeLa cells, and
CVB3-HL1 was collected from the supernatant of HL-1CVB3 cells (passages
9 to 11). Viruses were concentrated by ultracentrifugation via a sucrose
gradient procedure. Both virus strains were quantified by standard plaque
assays using HeLa cells, as the genome-to-PFU ratios for the two virus strains
were found to be similar by real-time reverse transcription-PCR (RT-PCR)
(data not shown).
CVB3 variant CVB3-PD was kindly provided by Michaela Schmidtke (Insti-
tute of Virology and Antiviral Therapy, Friedrich Schiller University, Jena,
Germany).
Cell cultures. HeLa, C2C12, and CHO-K1 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco BRL, Karlsruhe, Germany) supple-
mented with 5% fetal calf serum (FCS) and 1% penicillin-streptomycin. The
HL-1 cell line, a cardiac muscle cell line established from an AT-1 mouse atrial
cardiomyocyte tumor lineage, was a kind gift from William C. Claycomb (LSU
Health Science Center, Department of Biochemistry and Molecular Biology,
New Orleans, LA). HL-1, HL-1CVB3, and HL-1cure cells were maintained in
Claycomb medium supplemented with 10% FCS (JRH Bioscience, Lenexa, KS),
1% (each) penicillin-streptomycin, 0.1 mM norepinephrine (Sigma, Munich,
Germany), and 2 mM L-glutamine (Invitrogen, Karlsruhe, Germany). Embryonal
mouse cardiomyocytes (EMCMs) were isolated from fetal C57BL/6 mice. Be-
tween days 13 and 14 after fertilization, embryonic mouse hearts were isolated
and incubated in EDTA-trypsin at 4°C overnight. After additional incubation for
15 min in a Thermo shaker (Eppendorf, Hamburg, Germany) at 37°C and 450
rpm, 500 l of growth medium (DMEM without glutamine, 10% fetal bovine
serum [FBS], 1% penicillin-streptomycin) was added to each heart. The digested
heart tissue was transferred to a 75-ml cell culture flask. In order to separate the
fibroblasts from cardiomyocytes, the cells were incubated for 1 h at 37°C and 5%
CO2; after fibroblasts adhered, the supernatant containing cardiomyocytes was
transferred to 12-well plates and cultured for 5 days by changing growth medium
containing 5-bromo-2-deoxyuridine (BrdU) (BD Pharmingen, Heidelberg, Ger-
many) (0.1 mmol/liter) every second day. Neonatal rat cardiomyocytes (NRCM)
were generated and maintained as described previously (18).
Plasmid transfection. CHO-K1 cells were transfected with pZS2-mCAR1 (16)
or pZS2 (19) by the use of Lipofectamine LTX with Plus reagent (Invitrogen
GmbH, Karlsruhe, Germany) according to the recommendations of the supplier.
Transfections were performed using 24-well plates with a plasmid quantity of 0.5
g/well.
Production of sCAR-Fc. HeLa cells were transduced with an adenoviral vector
(AdG12) expressing the fusion protein of the extracellular domain of CAR and
the carboxyl terminus of the human IgG1 Fc domain (sCAR-Fc) in the presence
of doxycycline (Dox) (52). After transduction, cells were cultured for 3 days and
Dox was added daily at a concentration of 1 g/ml (Sigma). At days 2 and 3 after
transduction, the cell culture supernatants were collected and fresh medium
containing Dox was added. The collected supernatants containing sCAR-Fc were
pooled, and 2-ml aliquots were stored at 30°C. The sCAR-Fc concentration in
the cell culture supernatant was measured with a human IgG enzyme-linked
immunosorbent assay (ELISA) (Bethyl Laboratories Inc., Montgomery, TX)
according to the supplier’s instructions.
Virus plaque assay. Virus plaque assays were carried out as described
previously (17). Briefly, HeLa cells were cultured in six-well culture plates as
confluent monolayers at a density of 1  106 cells/well. After 24 h, medium
was removed and cells were overlaid with 1 ml of diluted supernatant har-
vested from HL-1 cell culture or from homogenized mouse hearts and then
incubated at 37°C for 30 min and, after removal of the supernatant, overlaid
with 2 ml of agar containing Eagle’s minimal essential medium (MEM).
Three days later, the cells were stained with 0.025% neutral red in phosphate-
buffered saline (PBS). Virus titers were determined by plaque counting at 3 h
after staining. Data shown represent the results of two plaque assays, each
performed in duplicate.
Real-time RT-PCR. Total RNA was isolated with Trizol reagent (Invitrogen,
Karlsruhe, Germany) according to the company’s recommendations followed by
DNase I digestion (Peqlab, Erlangen, Germany). RNA was then reverse tran-
scribed using a High-Capacity cDNA reverse transcription kit (Applied Biosys-
tems Inc., Foster City, CA). For quantification of gene expression, real-time PCR
was performed using a Mastercycler ep Gradient S system (Eppendorf) and
TaqMan Gene Expression Master Mix (Applied Biosystems Inc.) under the
standard conditions determined by the supplier. After AmpliTaq Gold activation
for 4 min at 94°C, 40 cycles were run at a denaturing temperature of 94°C (for
15 s) and an annealing and extension temperature of 60°C (for 1 min). Expres-
sion levels of CAR, and of GAPDH (glyceraldehyde-3-phosphate dehydroge-
nase) as a control housekeeping gene for normalization, were determined by
real-time PCR with minor groove binder (MGB) probes (Applied Biosystems).
PCRs were performed in triplicate, and analysis was carried out using the 2CT
threshold cycle method (37).
CVB3-RNA quantification. For quantitative analysis of CVB3 RNA in tissue
or cells, total RNA was isolated with a High Pure viral nucleic acid kit (Roche)
according to the suggestions of the supplier and CVB3 RNA levels were mea-
sured by light-cycle PCR using an artus Enterovirus LC RT-PCR kit (Qiagen,
Hilden, Germany).
Cell viability assay. The cell viability was carried out by the use of a XTT cell
proliferation kit (Roche, Mannheim, Germany) following the manufacturer’s
instructions. The absorbance measured at 492 nm is proportional to the number
of metabolically active cells and therefore to cell viability.
In situ hybridization. CVB3 plus-strand and minus-strand genomic RNA was
detected by in situ hybridization using strand-specific single-stranded 35S-labeled
RNA probes as described previously (33).
Immunofluorescence. HL-1 cells were fixed with 1 ml of Tris-buffered saline
(TBS) solution containing 4% formaldehyde and permeabilized with 0.5% Tri-
ton X-100. After being blocked in TBS buffer with 5% FCS and 0.1% Triton
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X-100, cells were incubated with NCL-entero anti-enterovirus (VP1) mouse
monoclonal antibody (Novocastra, Newcastle, United Kingdom) at a dilution of
1:10 in blocking solution for 1 h. After extensive rinsing was performed, the cells
were incubated with goat anti-mouse secondary antibody conjugated with Alexa-
Fluor 488 or Alexa-Fluor 594 (Molecular Probes, Karlsruhe, Germany) at a
dilution of 1:400 for 1 h. Cell nuclei were stained with DAPI (4,6-diamidino-2-
phenylindole) (Sigma) (0.5 g/ml). To stain the actin cytoskeleton, cells were
incubated with Alexa-Fluor 488-conjugated phalloidin (Molecular Probes) at a
dilution of 1:200 for 20 min. For propidium iodide (PI) staining, cells were
washed with PBS and incubated with PBS–0.5% PI (Molecular Probes) at 37°C
for 30 min.
Western blot analysis. Cells were scraped from a confluent T25 flask and lysed
with lysis buffer (20 mM Tris [ph 8], 10 mM NaCl, 0.5% [vol/vol] Triton X-100,
5 mM EDTA, 3 mM MgCl2). Protein (20 g) was separated on NuPage Bis-Tris
gels (Invitrogen) (4% to 12%) under reducing conditions and transferred onto a
polyvinylidene difluoride (PVDF) membrane (Bio-Rad Laboratories, Hercules,
CA). For detection of CAR, SERCA2a, and GAPDH, after the membranes
were blocked with 5% dry milk–TBS, they were incubated with H-300 anti-
CAR antibody (Santa Cruz, Santa Cruz, CA) at a dilution of 1:200, anti-
SERCA2a antibody (Abcam, Cambridge, MA) at a dilution of 1:20,000, and
anti-GAPDH antibody (Millipore, Billerica, MA) at a dilution of 1:7,500. After
washing was performed three times with TBS, the membranes were incubated
with species-specific horseradish peroxidase (HRP)-conjugated secondary anti-
bodies (Dako, Hamburg, Germany) in a dilution of 1:10,000 in 5% dry milk–TBS
at room temperature for 1 h. After extensive washing, detection by chemilumi-
nescence was achieved using Rodeo ECL Western blotting reagent (USB Cor-
poration, Santa Clara, CA).
Murine viral myocarditis model. Male BALB/c mice (6 weeks old) were
infected intraperitoneally (i.p.) with CVB3 and CVB3-HL1 at 5  105 PFU.
Seven days after CVB3 infection, the animals were killed and hearts were
analyzed for the presence of infectious CVB3 and CVB3 genomes in the
ventricles. For validation of inflammation, the basal parts of the hearts were
fixed in 4% formalin, embedded in paraffin, sectioned, and stained with
hematoxylin and eosin. Animal experiments were performed in accordance
with the principles of laboratory animal care and the German law on animal
protection.
RESULTS
Characterization of a persistently CVB3-infected cardiomy-
ocyte cell line. The HL-1 mouse atrial cardiomyocyte cell line
was infected with CVB3 at different multiplicities of infection
(MOI) (10, 1, and 0.1) and grown for 2 days at 37°C in Clay-
comb medium supplemented with 2% FCS. After trypsiniza-
tion and reseeding, only the HL-1 cells infected at an MOI of
0.1 were able to adhere and grow to a confluent monolayer.
The new cell culture, referred to as HL-1CVB3, could be main-
tained and passaged using the same procedures used with the
naive parental HL-1 cell line. Although morphologically indis-
tinguishable from the parental HL-1 cell line by light micros-
copy (Fig. 1A), the HL-1CVB3 cells consistently released large
amounts of progeny virus (106 to 108 PFU/ml) over a period of
11 weeks. During that period, aliquots of cells were frozen at
subculture passages 5 and 13, and thawed cells showed no
decline in virus production or cell growth compared to the
original HL-1CVB3 cells (Fig. 1B). Analysis of CVB3 VP1 ex-
pression in HL-1CVB3 cells as determined by immunofluores-
cence revealed that only approximately 10% of the HL-1CVB3
cells expressed the viral capsid protein VP1; that finding was
confirmed by in situ hybridization with CVB3 positive- and
negative-strand genomic probes (Fig. 1A). We did consistently
note, however, that the number of cells that were found to
contain positive CVB3 strands was greater than the number
that were found to contain the negative strand in the infected
subpopulation of HL-1CVB3 cells (Fig. 1A). Based on these
observations, CVB3 infection of HL-1CVB3 cells displays typi-
cal persistent carrier-state infection characteristics.
CVB3 induces a typical cytopathic effect (CPE), including
disruption of the cytoskeleton, in infected cells. The cytoskel-
eton of CVB3-infected HL-1CVB3 cells was first stained with
fluorescent phalloidin, which binds directly to the cellular F-
actin filaments, and then costained for enterovirus VP1. VP1-
negative cells showed intact actin filaments in the HL-1CVB3
cell culture, whereas the VP1-positive subpopulation showed a
depolymerized actin cytoskeleton with disrupted actin fila-
ments and accumulations of actin conglomerates (Fig. 2A).
Loss of membrane integrity induced by the presence of CVB3
in HL-1CVB3 cells was measured by nuclear propidium iodide
(PI) staining (Fig. 2B); when cells were fixed and costained for
VP1, PI was observed only inside VP1-positive cells. Moreover,
late-stage destruction of CVB3-infected HL-1CVB3 cells could
be confirmed by detection of karyopyknosis and fragmentation
of the nucleus following DAPI staining (Fig. 2B, right upper
and lower panels). Lack of PI staining in individual CVB3-
infected HL-1CVB3 cells (Fig. 2B, left lower panel), however,
may reflect an earlier phase of CVB3 infection, when cell death
FIG. 1. Characterization of persistently CVB3-infected HL-
1CVB3 cardiac mouse cell line. (A) Cell morphology, virus capsid
protein (VP1) expression, and determination of CVB3-RNA in
HL-1CVB3 cells. Light microscopy showed no difference between
HL-1CVB3 and uninfected HL-1 cells in cell morphology. CVB3 VP1
expression was determined by indirect immunofluorescence after
incubation of cells with an anti-enterovirus VP1 antibody and a
secondary antibody conjugated with Alexa-Fluor594 (red). Cell nu-
clei were costained with DAPI (blue). The presence of CVB3
positive- and negative-strand RNA was determined by in situ hy-
bridization using specific 35S-labeled enterovirus positive- or nega-
tive-strand RNA hybridization probes. Magnification, 100-fold.
(B) CVB3 titer in HL-1CVB3 cells. Levels of infectious CVB3 in the
supernatant of HL-1CVB3 cells were determined by plaque assays
after virus persistence was established. During the investigation
period of 11 weeks, cells were passaged every 3 to 4 days. The
culture supernatant of HL-1CVB3 cells showed continuous high lev-
els of CVB3 ranging between 106 and 108 PFU/ml. At indicated
time points (snowflakes), cells were frozen and reseeded.
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is not yet induced. CPE was detected during establishment of
the persistently infected cell culture and could be observed in
the cell culture as a rare event during the whole investigation
period.
CVB3-HL1 cells show increased cardiomyocyte-specific rep-
lication in vitro but lack cardiopathogenesis in vivo. An altered
replication rate is often observed during cell culture adaptation
of viral strains. To study cell-type-specific CVB3 adaptation,
we next investigated the replication efficiency and virulence of
CVB3 progeny from HL-1CVB3 cells. HL-1CVB3 cell culture
supernatants from passages 9 to 11 were collected, purified,
and concentrated by ultracentrifugation using sucrose banding.
The progeny virus (CVB3-HL1) showed a 10- to 100-fold re-
duction in virus replication (Fig. 3A) and produced smaller
virus plaques relative to those of the parental CVB3 in HeLa
cells (Fig. 3B). Infection of HL-1 cells and neonatal rat cardi-
omyocytes (NRCM) with CVB3-HL1 yielded 100- to 10,000-
fold more viral progeny at 24 and 48 h postinfection relative to
the results seen with cells infected with the parental CVB3
strain (Fig. 3A). CVB3-HL1 infection of embryonic mouse
cardiomyocytes (EMCM) also showed a consistently higher
yield of progeny relative to parental CVB3 infection (albeit the
difference was smaller than that seen with the other two car-
diac cell lines) but yielded lower progeny numbers than paren-
tal CVB3 infection of HeLa cells (Fig. 3A). Moreover, 30% to
40% of HL-1 cells infected with CVB3-HL1 (MOI of 1)
showed VP1 expression at 24 h postinfection compared to
approximately 1% of VP1-positive HL-1 cells infected with
CVB3 (Fig. 3C, right panel). Cell viability assays also revealed
much greater cytotoxicity of CVB3-HL1 in HL-1 cells, while
parental CVB3 cytotoxicity appeared negligible (Fig. 3C, left
panel). These data indicate that CVB3-HL1 represents a new
CVB3 variant that exhibits increased replication rates and vir-
ulence for cardiomyocytes in vitro.
To compare the cardiopathogenic potential and cardiotro-
pism of CVB3-HL1 to those of parental CVB3 in vivo, BALB/c
mice were infected with 5 105 PFU CVB3-HL1 or CVB3 and
investigated 7 days later for virus replication and inflammation.
Infectious CVB3 particles (approximately 103/mg of heart tis-
sue) were detected in CVB3-infected mice, confirming cardio-
tropism and successful viral replication of parental CVB3 in
the murine heart. Surprisingly, infectious CVB3-HL1 particles
were undetectable in the heart of CVB3-HL1-infected animals.
Real-time RT-PCR confirmed the absence of CVB3-HL1 ge-
nomes in mice infected with the persistent strain but confirmed
the presence of abundant amounts of CVB3 RNA in animals
infected with the parental strain (Fig. 4A). To document
whether the absence of CVB3-HL1 in the heart correlated with
a lack of pathological alterations, histological analysis of heart
tissues of CVB3- and CVB3-HL1-infected animals was carried
out. All 9 CVB3-infected animals showed strong pericardial
inflammation and some overt inflammatory foci in the myo-
cardium. In contrast, only 4 of the 9 animals infected with
CVB3-HL1 showed inflammation in the heart. Furthermore,
the area of leukocyte infiltration for those 4 animals was dis-
tinctly smaller than the area seen in hearts from parental
CVB3-infected animals (Fig. 4B). Interestingly, histological
examinations and in situ hybridization assays for detection of
the CVB3 genome revealed strong tissue destruction and the
presence of large amounts of CVB3 in the pancreas (results
not shown) in both CVB3- and CVB-HL1-infected animals,
thus indicating similar levels of in vivo infectivity of CVB3 and
CVB3-HL1 in noncardiac CVB3 target organs. In summary,
these data demonstrate that increased cardiospecific replica-
tion of CVB3-HL1 in vitro did not result in enhanced cardio-
tropic virulence in vivo.
A decrease of cellular CAR expression during CVB3 persis-
tence in HL-1CVB3 cells induces CVB3-HL1 receptor shift.
CVB3 uses cellular-decay-accelerating factor (DAF) and CAR
as receptors to infect cells. However, murine DAF is not
broadly expressed in mice (36), and murine DAF and related
homologues are unable to bind to CVB3 (61), leaving murine
CAR as the only known potential viable receptor in mice. As
virus uptake is an important mechanism in the virus replication
cycle, we hypothesized that changes in cellular CAR expression
may be involved in the adaptation of HL-1CVB3 cells to CVB3
infection. Quantification of CAR-mRNA expression by real-
time RT-PCR revealed a 60% decrease in CAR-mRNA ex-
pression at passage 3 and a decrease of more than 80% at
passage 7 after infection of HL-1 cells with CVB3 relative to
the results seen with the parental noninfected HL-1 cell line. A
FIG. 2. Pathogenic alterations caused by CVB3 infection in the
persistently infected HL-1CVB3 cell line. (A) Disruption of cytoskele-
ton in CVB3-infected HL-1CVB3 cells. Cells were stained for detection
of CVB3 VP1 expression as described for Fig. 1A. Staining of F-actin
filaments was carried out with Alexa-Fluor488 (green)-conjugated phal-
loidin. CVB3-infected cells in the culture showed disruption of actin
filaments and accumulation of actin conglomerates (green spots and
yellow arrows), whereas uninfected cells showed intact filamentous
actin fibers (white arrows). Magnification, 1,000-fold. (B) Detection of
cytopathic effect in CVB3-infected HL-1CVB3 cells. CVB3-infected
cells were incubated with propidium iodide (PI) (red) and then stained
with enterovirus-specific VP1 antibody and a secondary antibody con-
jugated with Alexa-Fluor488 (green) (left panels) and then with DAPI
(blue) (right panels). Red-green and magenta-blue costaining reveals
CVB3-infected dead cells (yellow arrows), whereas cells stained solely
green (white arrow, lower left panel) may represent CVB3-infected
cells at an early replication stage without signs of cell death. Magnifi-
cation, 400-fold.
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further and lasting reduction of more than 90% was seen after
passage 7 (Fig. 5A). As CAR is essential for CVB3 uptake into
target cells, the continuous production of high CVB3 titers in
HL-1CVB3 cells (Fig. 1B) suggested that the CAR-independent
uptake mechanisms had been acquired by the CVB3-HL1-
adapted strain in HL-1CVB3 cells. To test this assumption, we
investigated the ability of CVB3-HL1 to infect and replicate in
mouse myoblast C2C12 cells and CHO-K1 cells. CHO-K1 cells
do not express CAR (57), whereas a low level of CAR expres-
sion in C2C12 cells was reported previously (32, 44). Real-time
RT-PCR analysis, however, demonstrated an absence of CAR
expression in the C2C12 cells used in this study (results not
shown). Both cell lines were incubated with the parental CVB3
strain and with CVB3-HL1 at MOIs of 0.1 and 1. As a control
for determining CAR-independent CVB3 uptake, CHO-K1
cells were also infected with CVB3-PD, a CVB3 variant that
uses heparan sulfate (HS) as a receptor to infect CAR-negative
cells (67). Measurement of progeny virus titers at 24 h after
infection demonstrated that CVB3-HL1, but not the parental
CVB3, efficiently infected C2C12 cells. CHO-K1 cells were
efficiently infected with CVB3-HL1 and CVB3-PD but were
completely resistant to CVB3 (Fig. 5B). These data demon-
strate that CVB3-HL1 is able to infect cells via CAR-indepen-
dent uptake mechanisms.
To examine whether HS may act as a receptor of the CVB3-
HL1 variant, we pretreated CVB3-HL1 and CVB3-PD with
heparin, a soluble HS receptor analogue, before incubating
CHO-K1 cells. As expected, CVB3-PD infection was strongly
inhibited by heparin treatment. CVB3-HL1 infection, however,
was unaffected (Fig. 5C), indicating that CVB-HL1 is able to
infect cells via an unknown CAR- and HS-independent uptake
mechanism.
Next, we investigated whether a CVB3-HL1 receptor shift
was accompanied by an inability of CVB3-HL1 to infect cells
via CAR. Therefore, CHO-K1 cells were transfected with
mouse CAR-expressing plasmids and then infected with
CVB3-HL1, CVB3, and CVB3-PD. The progeny virus titers
were determined 8 h later. All analyzed CVB3 subtypes repli-
cated more efficiently in CAR-expressing than in CAR nega-
tive-control-transfected CHO-K1 cells (Fig. 5D), revealing that
FIG. 3. Alteration of infectivity and replication activity of CVB3-HL1. (A) Replication of CVB3-HL1 in cardiac and HeLa cells in vitro. HeLa
cells, native HL-1 cells, NRCM, and EMCM were infected with CVB3 and CVB3-HL1 at an MOI of 0.1. Plaque assays were performed 24 and
48 h later. In comparison to CVB3, CVB3-HL1 showed distinctly increased replication in the cardiac cell lines but lower replication in HeLa cells.
Values are given as means  standard deviations (SD) of the results of two independent experiments, each performed in duplicate. p.i.,
postinfection. (B) Representative plaque assay of CVB3 (dilution, 106) and CVB3-HL1 (dilution, 102) in HeLa cells. The CVB3-HL1 variant
showed a smaller plaque size than CVB3. (C) Infectivity of CVB3-HL1 versus CVB3 in HL-1 cells. (Left panel) HL-1 cells were seeded in 96-well
plates and infected with different doses of CVB3 and CVB3-HL1. Cell viability was measured by cell proliferation assays performed with uninfected
cells (mock) as a control (set as 100%). CVB3-HL1, but not CVB3, induced cell lysis in HL-1 cells. Values are given as means  SD of the results
of two experiments, each performed in quadruplicate. (Right panel) HL-1 cells were infected with CVB3 and CVB3-HL1 at an MOI of 1. VP1
capsid protein was detected by immunofluorescence using an anti-enterovirus VP1 antibody (green) 24 h later. Nuclei were stained with DAPI
(blue). Magnification, 100-fold. Compared to CVB3 infection, CVB3-HL1 infection showed a drastic increase in the number of VP1-positive HL-1
cells.
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the CVB3-HL1 variant was still capable of using CAR as a
receptor for infection.
Complete cure of persistently infected HL-1 cells by
sCAR-Fc treatment. We recently showed that treatment of
a persistently CVB3-infected human myocardial fibroblast
(HMF) cell line with AdG12, a recombinant adenovirus vector
expressing sCAR-Fc, decreased persistent CVB3 infection;
however, sCAR-Fc was not capable of clearing the CVB3 in-
fection (64). To examine whether sCAR-Fc was able to bind
and inhibit the CVB3-HL1 variant, we transduced HL-1CVB3
cells with AdG12 (MOI, 30) and induced the expression of
sCAR-Fc with doxycycline (Dox). A single transduction re-
sulted in strong sCAR-Fc expression and reduced CVB3-HL1
titers by about a millionfold within 6 days. Thereafter,
sCAR-Fc expression rapidly declined, becoming undetectable
at day 12 after vector transduction. In parallel, CVB3-HL1
titers were found to have recovered and climbed to almost
pretreatment levels by day 12. Repeated transduction of HL-
1CVB3 cells with AdG12, in the presence of Dox, at days 2 and
6 after the first AdG12 transduction resulted in extended pro-
duction of high-level sCAR-Fc expression and in complete
clearance of CVB3 from HL-1CVB3 cells at day 6 (Fig. 6A).
External repeated addition of sCAR-Fc containing culture me-
dium also resulted in total CVB3 clearance, indicating that
intracellular delivery was not required for therapeutic efficacy
(Fig. 6B). Lack of CVB3-HL1 RNA in total RNA extracts of
sCAR-Fc-treated HL-1CVB3 cells at day 4 after the beginning
of sCAR-Fc treatment as detected by quantitative RT-PCR
(Fig. 6C) confirmed the complete clearance of HL-1CVB3 cells
by recombinant sCAR-Fc. Moreover, we were unable to detect
infectious CVB3-HL1 particles in the cell supernatant after
“cure” of HL-1CVB3 cells (here, cured HL-1CVB3 cells are
FIG. 4. Cardiotropism and cardiopathogenicity of CVB3-HL1 in
vivo. (A) CVB3-HL1 lacks cardiotropism in vivo. Nine BALB/c mice
were infected with 5  105 PFU of CVB3 or CVB-HL1. As a control,
6 mice were treated with PBS. Seven days after CVB3 infection, organs
were harvested for virus detection and histopathological analysis.
CVB3 positive-strand RNA and infectious virus numbers in the heart
tissue were quantified by real-time RT-PCR and a standard plaque
assay, respectively. Quantitative analysis showed a complete absence of
CVB3-HL1 in the heart, whereas CVB3 RNA (right) and infectious
CVB3 particles (left) were abundantly detected. n.d., not detectable.
(B) Heart sections of CVB3- and CVB3-HL1-infected mice were
stained with hematoxylin and eosin (magnification, 100-fold). CVB3-
infected animals showed an expanded inflammation area at the
pericardium (thick arrows) and some inflammatory spots with
mononuclear cells in the myocardium (thin arrows). Heart tissues of
CVB3-HL1-infected animals showed faint pericardial infiltrations
with mononuclear cells. FIG. 5. CVB3-HL1 persistence in HL-1CVB3 cells is associated with
CAR downregulation and virus receptor shift. (A) CAR expression in
persistently infected HL-1CVB3 cells. Total RNA was isolated from HL-
1CVB3 cells at the indicated passages after CVB3 infection, and CAR
mRNA was quantified by real-time RT-PCR. CAR-mRNA expression of
noninfected HL-1 cells was set as 100%. (B) CVB3-HL1 utilizes a CAR-
independent method to infect cells. C2C12 and CHO-K1 cells were in-
fected with CVB3-HL1 and CVB3 at MOIs of 0.1 and 1. Replication
efficiencies were measured by plaque assays 24 h later. As a control for
CAR-independent virus uptake determinations, CHO-K1 cells were in-
fected with strain CVB3-PD, which is known to infect CAR-negative cells
via binding to heparan sulfate. The CVB3-HL1 variant, but not parental
CVB3, replicated efficiently in CAR-negative cells. n.d., not detectable.
(C) Lack of CVB3-HL1 inhibition by heparin. CVB3-PD and CVB3-HL1
(each at an MOI of 1) were preincubated with heparin at different con-
centrations for 1 h. Subsequently, CHO-K1 cells were infected, and rep-
lication efficiencies were measured by plaque assays 24 h later. Whereas
infection of CVB3-HL1 was unaffected by heparin treatment, CVB3-PD
infection was inhibited by heparin in a dose-dependent manner. (D) In
spite of a CVB3-HL1 receptor shift during virus persistence in HL-1 cells,
CVB3-HL1 can use CAR as a receptor to infect cells. CHO-K1 cells were
transfected with mouse CAR1 (pZS2-mCAR1)-expressing plasmid or
control plasmid (pZS2) and infected 48 h later with the indicated CVB3
subtypes (MOI, 1). At 8 h later, the amounts of infectious virus particles
were determined by plaque assays. Note that there was a significant (P
0.005) difference between pZS2 and pZS2-mCAR1 results for the
CVB3-PD group.
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termed “HL-1cure”) over an additional period of 3 weeks (data
not shown). These data demonstrate that sCAR-Fc efficiently
neutralizes CVB3-HL1 and is able to clear persistently infected
HL-1CVB3 cells.
The HL-1cure cell line conserves resistant features of the
HL-1CVB3 cell line. In order to elucidate whether resistant
features of HL-1CVB3 cells were conserved after removing
the viral pressure, HL-1cure cells were further characterized.
To this end, we first determined the expression of CAR-
mRNA by real-time RT-PCR and found a reduction of more
than 90% in CAR mRNA expression compared to the ex-
pression seen with parental HL-1 cells (Fig. 7A). Immuno-
blotting confirmed the CAR protein downregulation in HL-
1cure cells (Fig. 7B), while levels of expression of SERCA2a
(a cardiomyocyte-specific protein) in HL-1cure cells were
similar to those seen with HL-1 cells. We next investigated
the ability of CVB3 and CVB3-HL1 to infect HL-1cure cells.
Both virus variants were able to infect the cell line, but the
virus infection rates were about 32- and 95-fold lower, re-
spectively, than those seen with HL-1 cells (Fig. 7C). More-
over, whereas HL-1 cells were lysed by CVB3-HL1, HL-1cure
cells were resistant to CVB3-HL1-induced cell lysis (Fig.
7D). The data confirm that the HL-1cure cell line differs
from the HL-1 cell line and had conserved the resistance
features of the persistently infected HL1CVB3 cell line.
DISCUSSION
Virus persistence may be viewed at three distinct levels:
persistence in the population as a whole, persistence in the
individual host, and persistence within a cell or group of cells
(21, 33, 38). Viruses have evolved a wide variety of strategies
that enable them to persist and cause diseases. A broad range
of cytolytic viruses, including enteroviruses, establish persistent
types of infections both in vivo and in vitro (4, 5, 8, 15, 28, 33).
In most cases, this is induced by selection of virus mutants that
are less cytopathic (2, 20, 53). Other mechanisms comprise
coevolution of both cells and viruses (1, 6, 50). In coevolution,
persistent infections are accompanied by alterations of both
cells and viruses such that cellular resistance to viral replica-
tion is balanced by an enhanced capacity of the virus to infect
the resistant cells.
To investigate the mechanism of CVB3 persistence in heart
cells, CVB3 infection of primary human myocardial fibroblasts
(HMF) or immortalized HMF was established (26–28). Unfor-
tunately, cardiomyocytes but not fibroblasts represent the ma-
jor target cells of CVB3 in the heart (35); thus, the suitability
of persistently infected HMF cells for studying CVB3 infec-
tions in vitro is limited. To overcome this limitation, we estab-
lished a persistently CVB3-infected cardiac cell line (HL-
1CVB3) by infection of murine HL-1 cells with CVB3.
FIG. 6. Cure of HL-1CVB3 cells by sCAR-Fc. (A) Cure of HL-1CVB3 cells by sCAR-Fc expressed from an adenoviral vector. HL-1CVB3 cells on
passage 16 were transduced with sCAR-Fc-expressing doxycycline (Dox)-dependent AdG12 adenovector (MOI, 30). Cells were treated once or
three times at the indicated time points (arrows) and then cultured in the presence or absence of Dox as indicated. Samples of medium were taken
at indicated time points to determine the amount of infectious viral particles (lower diagram) and sCAR-Fc concentration (upper diagram) in the
cell culture supernatant by plaque assay and anti-human IgG ELISA, respectively. Threefold repetitive transductions, but not a single transduction,
performed with AdG12 resulted in a complete elimination of CVB3-HL1 from HL-1CVB3 cells at day 6 after AdG12 transduction. d p.t., day
posttransfection. (B) Cure of HL-1CVB3 cells by application of recombinant sCAR-Fc. Recombinant sCAR-Fc was produced by transduction of
HL-1 cells with AdG12 in the presence of Dox. The sCAR-Fc concentration in the supernatant was quantified, and sCAR-Fc (200 ng/ml) was
added to HL-1CVB3 HL cells (passage 8). The sCAR-Fc-containing medium was refreshed daily. Amounts of infectious virus particles in the cell
culture supernatant were quantified by plaque assays using HeLa cells. CVB3-HL1 titers in the supernatant of HL-1CVB3 cells rapidly decreased
and became undetectable at day 6 and thereafter (end of the investigation, day 13) from the beginning of sCAR-Fc treatment. Two independent
experiments (dashed and solid lines) were carried out. (C) Measurement of CVB3-HL1 RNA. HL-1CVB3 cells during passage 8 were treated by
daily applications of recombinant sCAR-Fc (200 ng/ml) to the cell culture medium as described for panel B. Total RNA from HL1CVB3 cells was
isolated at the indicated time points, and the CVB3 RNA was quantified by real-time RT-PCR. No viral RNA was detected on day 4 or on later
days after the beginning of sCAR-Fc treatment.
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Picornaviruses are able to induce two different types of persis-
tence in vitro. The carrier-state infection is characterized by
infection of a small proportion of the cell population. The
infected cells release virus and are killed, but the released virus
infects a small number of other cells. In a steady-state infec-
tion, all cells are infected, both virus and cell multiplication
proceed without the cell being killed, and the cell culture
continuously releases virus (21, 39). However, intermediate
models also exist (51). HL-1CVB3 cells showed the typical signs
of persistent carrier-state infection with high virus titers. The
numbers of infected cells in a carrier-state infection can range
from about 10% to 60% depending on the virus and host cell
(6, 27, 43, 40). In line with these observations, about 10% of
HL-1CVB3 cell expressed the VP1 viral capsid protein. More-
over, in situ hybridization revealed the presence of positive-
and negative-strand RNA, with distinctly higher percentages of
positive-strand RNAs, indicating acute, productive virus repli-
cation (35). As a further typical indication of a carrier-state
infection, HL-1CVB3 cells showed virus-induced cytopathic ef-
fects (CPEs), including alterations of the cytoskeleton, loss of
membrane integrity, and karyopyknosis in individual cells but
not overt lytic infection of the cell culture.
The results of our study demonstrate that both the HL-1
host cell line and the CVB3 virus have evolved during persis-
tent infection and that coevolution of target cells and virus
represents the major mechanism of CVB3 persistence in HL-1
cells. Many studies have found coevolution of cells and virus
during development of persistent virus infection in vitro, but
elucidations of the specific mechanisms have been sparse (6,
13, 24, 68). As found here, one key feature of cellular evolution
following CVB3 infection was downregulation of the CVB3
receptor CAR. Attachment to and internalization into host
cells are important determinants of viral infection, and an
alteration in receptor expression exerts a powerful cellular
defense mechanism against viral infections. CAR acts as an
essential receptor of CVB3 and mediates its internalization
into the target cell (3, 12). In vitro studies have demonstrated
that CAR knockdown resulted in decreased CVB3 infection,
viral replication, and virus-induced cell lysis (16, 65). More-
over, heart-specific CAR ablation in vivo makes mice resistant
to cardiac CVB3 infections (60).
An important aspect of development of resistance in the
HL-1CVB3 cell line was the very fast downregulation of CAR in
the CVB3-infected HL-1 cell culture: within 3 passages, CAR
expression declined by approximately 60%, and at passage 8
and later, a consistent decrease of more than 90% in expres-
sion relative to the expression level seen with uninfected HL-1
cells was observed. Although the molecular mechanism leading
to CAR downregulation was not determined in this study, it
can be supposed that the initial incubation of HL-1 cells with
CVB3 preferentially results in infection and subsequent dis-
ruption of cells with high levels of CAR expression. As CAR
expression is variable in cell cultures, it can be supposed that a
subpopulation of cells with low-level CAR expression or lack-
ing such expression is protected from virus infection and cell
lysis (19). As consequence, such cells proliferate in the culture
within several passages and finally determine the level of cel-
lular resistance to CVB3. Persistent infection of cell lines with
FIG. 7. Characterization of HL-1cure cells. (A) Expression of CAR mRNA in HL-1cure cells. Total RNA was isolated from HL-1cure cells at the
indicated passages after CVB3 infection, and CAR mRNA expression was quantified by real-time RT-PCR. CAR mRNA expression of
noninfected HL-1 cells was set as 100%. (B) Western blot analysis of CAR, SERCA2a, and GAPDH expression in HL-1 and HL-1cure cells.
Compared to HL-1 cells, HL-1cure cells showed decreased CAR expression but retained a similar level of expression of the SERCA2a cardiomyo-
cyte-specific protein. (C) Resistance of HL-1cure cells to CVB3 and CVB3-HL1 infection. HL-1 and HL-1cure cells were infected with CVB3 and
CVB3-HL1 at an MOI of 1. Virus titers in the cell culture supernatant were quantified by plaque assays 24 h later. Both viruses showed a significant
decrease of replication in HL-1cure cells compared to HL-1 cells. Values are given as means  SD of the results of two independent experiments,
each performed in duplicate. (D) HL-1cure cells resist CVB3-HL1-induced cell lysis. HL-1 and HL-1cure cells were seeded in 96-well plates and
infected with different doses of CVB3-HL1. Cell viability was measured by a cell proliferation assay (XTT), with uninfected cells (mock) as a
control (set as 100%). HL-1cure cells, but not HL-1 cells, resisted CVB3-HL1-induced cell lysis. Values are given as means  SD of the results of
two experiments, each performed in quadruplicate.
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other viruses, such as the mouse hepatitis virus (6, 55) and
hepatitis C virus (68), has also been shown to be associated
with cellular virus receptor downregulation. A closely similar
level of poliovirus persistence was previously seen to be asso-
ciated with specific mutations in the first extracellular domain
of the CD155 poliovirus receptor (50). This suggests that
blocking of virus binding, at the first step in infection, is a
recurring mechanism in the evolution of viruses that persis-
tently infect cell lines. Our data do not rule out the possibility
that other cellular functions directly or indirectly related to the
CVB3 replication cycle in persistently infected HL-1CVB3 cells
are also affected, as has been reported for other cell lines with
persistent virus infections (66, 68).
Based on our current knowledge, evolutionary pressure in
virus-infected cell lines primarily starts from the cytopathic
virus that infects and kills susceptible cells. If a cell culture is
able to develop resistance, then the virus must also adapt to
persist and to avoid being cleared by cell division and turnover
of the host cells. In agreement with this assumption, we found
that the adapted CVB3-HL1 virus was markedly different from
the parental virus strain: it could infect CHO-K1 cells, which
were completely resistant to parental CVB3, it had a lower
capacity to infect HeLa cells, and it was much more efficient at
infecting primary rodent heart-derived cells, as judged by prog-
eny production and the presence of VP1-positive and genome-
positive cells. An increased capacity to infect parental HL-1
cells was particularly notable, as CVB3 could infect only 1% of
cells compared to 30% to 40% infection by the CVB3-HL1
strain. As with mouse hepatitis virus (6), yellow fever virus
(63), and foot-and-mouth disease virus (59) adapted for per-
sistent infection, we noted that CVB3-HL1 exhibited a smaller
plaque size on HeLa cells than the parent strain. As reported
previously from investigations performed using foot-and-
mouth disease virus (59), propagation in the standard cell line
(HeLa) resulted in a reversion of plaque morphology and cell
tropism of CVB3-HL1 to those characteristic of the parental
CVB3 strain (data not shown). Since the CVB3-HL1 strain
replicates in CAR-negative cell lines, that finding suggests that
the virus gained a CAR-independent entry mechanism. This,
however, seems to be a crucial step in the viral coevolution
process, as it helps the virus to overcome the cellular resistance
acquired through CAR downregulation. Although CVB3-HL1
no longer required CAR for cell entry, it is important that
CVB-HL1 could still use CAR as a cellular receptor, that
CAR-based therapeutics were still capable of neutralizing the
virus, and that prolonged use of such therapeutics was capable
of completely clearing the adapted virus from the persistently
infected cell line. This suggests only minor alterations to the
capsid accompanying the altered cell tropism, as previously
noted for another CVB3 variant, CVB3-PD (57).
Most unexpectedly, the enhanced ability of CVB3-HL1 to
infect cardiac cells in vitro was not mirrored by an enhanced
cardiotropism or cardiopathogenic capacity in vivo in BALB/c
mice, demonstrating that the degree of CVB3-HL1 adaptation
and virulence in vitro did not represent an indicator of the
presence of in vivo cardiac infections. However, 4 of 9 CVB3-
HL1-infected animals exhibited acute cardiac inflammations,
suggesting that, at least in some mice, the CVB3-HL1 strain
infected the heart transiently. Both host factors and viral ge-
netic determinants influence the outcome of CVB3-induced
myocarditis in genetically different inbred mouse strains (9, 30,
34). In this context, it was previously shown that different
CVB3 strains (generated in vitro or in vivo) showing variations
in infectivity, cell specificity, and pathology induce highly vari-
able infections in vivo (56).
The mechanisms involved in heart resistance to CVB3-HL1
are not known, but attenuation of viruses after passages
through cell culture is an often-observed phenomenon (10, 11,
25); for example, the attenuated Sabine 1 strain, the oral live
polio vaccine, was derived by several passages through cell
culture (45). One possible explanation for our findings is that
heart resistance may have resulted from an accelerated clear-
ance of the virus by specific immunological mechanisms di-
rected against the CVB3-HL1 mutant; however, the additional
inability of CVB3-HL1 to infect the heart efficiently, or a
combination of the two mechanisms, may also be responsible
for the heart resistance. The ability of CVB3-HL1 to infect
other target organs in vivo in a manner typical of CVB3 was
confirmed by detection of strong CVB3-HL1 infection of the
pancreas. Therefore, the in vivo inability of CVB3-HL1 to
infect target cells per se is rather unlikely to be the most
important factor in heart resistance; antiviral immunological
mechanisms are likely much more crucial.
In summary, we established and characterized a persistent
CVB3 infection in a cardiomyocyte cell line for the first
time. Persistent infection of cardiomyocytes was accompa-
nied by downregulation or elimination of CAR-expressing
cells in parallel to the coevolution of CAR-independent
viral entry. The newly generated, persistently CVB3-in-
fected HL-1CVB3 cell line now presents the possibility of
studying virus host interaction in a more relevant cardiac in
vitro system than was available before. This may help to
improve understanding of the mechanisms involved in
CVB3 infections of the heart. Most importantly, sCAR-Fc
was found to be capable of completely eliminating the per-
sistent adapted CVB3 strains without a requirement for
intracellular delivery, supporting its candidacy to be devel-
oped as an in vivo therapeutic in the future.
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